0.369
price up icon3.36%   0.012
after-market アフターアワーズ: .36 -0.009 -2.44%
loading
前日終値:
$0.357
開ける:
$0.355
24時間の取引高:
78,246
Relative Volume:
0.79
時価総額:
$13.18M
収益:
$45.91M
当期純損益:
$-4.62M
株価収益率:
-2.632
EPS:
-0.1402
ネットキャッシュフロー:
$-21.51M
1週間 パフォーマンス:
-1.76%
1か月 パフォーマンス:
-12.14%
6か月 パフォーマンス:
-48.68%
1年 パフォーマンス:
-65.19%
1日の値動き範囲:
Value
$0.355
$0.3751
1週間の範囲:
Value
$0.346
$0.393
52週間の値動き範囲:
Value
$0.3442
$1.50

Equillium Inc Stock (EQ) Company Profile

Name
名前
Equillium Inc
Name
セクター
Healthcare (1170)
Name
電話
(858) 412-5302
Name
住所
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Name
職員
35
Name
Twitter
Name
次回の収益日
2025-03-26
Name
最新のSEC提出書
Name
EQ's Discussions on Twitter

EQ を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
EQ
Equillium Inc
0.369 13.42M 45.91M -4.62M -21.51M -0.1402
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.27 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.85 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.98 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
484.93 63.90B 14.09B 4.50B 2.96B 39.28

Equillium Inc Stock (EQ) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-28 ダウングレード Leerink Partners Outperform → Market Perform
2021-10-29 再開されました Stifel Buy
2021-09-15 開始されました Cantor Fitzgerald Overweight
2020-07-14 繰り返されました H.C. Wainwright Buy
2020-07-10 再開されました Stifel Buy
2019-02-22 開始されました SVB Leerink Outperform
すべてを表示

Equillium Inc (EQ) 最新ニュース

pulisher
May 29, 2025

Equillium (NASDAQ:EQ) Trading Down 6.1% – Time to Sell? - Defense World

May 29, 2025
pulisher
May 22, 2025

Equillium expands equity incentive plan by 1.78 million shares - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Equillium Holds Annual Stockholders Meeting on Key Proposals - TipRanks

May 22, 2025
pulisher
May 07, 2025

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - BioSpace

May 07, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Sells 59,773 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World

May 07, 2025
pulisher
May 05, 2025

Equillium stock touches 52-week low at $0.52 amid market challenges - MSN

May 05, 2025
pulisher
May 04, 2025

Head-To-Head Survey: Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) - Defense World

May 04, 2025
pulisher
May 01, 2025

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - BioSpace

May 01, 2025
pulisher
Apr 25, 2025

FDA declines itolizumab accelerated approval, says Equillium - The Pharma Letter

Apr 25, 2025
pulisher
Apr 24, 2025

Equillium shares fall following FDA feedback By Investing.com - Investing.com India

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium shares fall following FDA feedback - Investing.com Australia

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium Announces Feedback from the U.S. Food and Drug Adminis - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium (EQ) Faces Setback as FDA Declines Accelerated Approva - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

FDA declines Equillium’s itolizumab accelerated approval By Investing.com - Investing.com Canada

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium (EQ) Faces FDA Setback for Itolizumab in Graft-versus-Host Disease Treatment | EQ Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

FDA declines Equillium’s itolizumab accelerated approval - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire

Apr 24, 2025
pulisher
Apr 22, 2025

Equillium (NASDAQ:EQ) Shares Down 3.7% – Here’s Why - Defense World

Apr 22, 2025
pulisher
Apr 01, 2025

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Leerink Partners Reaffirms “Market Perform” Rating for Equillium (NASDAQ:EQ) - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

The week in pharma: action, reaction and insight – week to March 28 - The Pharma Letter

Mar 30, 2025
pulisher
Mar 30, 2025

Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium stock tumbles on Phase 3 study results By Investing.com - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium stock tumbles on Phase 3 study results - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace

Mar 28, 2025
pulisher
Mar 27, 2025

Equillium Reports 2024 Financials and Clinical Milestones - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough GVHD Treatment: New Drug Extends Response Duration by 4.7x in Phase 3 Trial - Stock Titan

Mar 27, 2025

Equillium Inc (EQ) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.16
price up icon 0.00%
$573.50
price down icon 0.54%
$36.08
price up icon 15.90%
$305.31
price up icon 0.51%
$4.75
price up icon 3.70%
$484.93
price down icon 0.60%
大文字化:     |  ボリューム (24 時間):